Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · IEX Real-Time Price · USD
15.40
+0.82 (5.62%)
May 3, 2024, 4:00 PM EDT - Market closed
Viridian Therapeutics Revenue
In the year 2023, Viridian Therapeutics had annual revenue of $314.00K, a decrease of -82.28%. Revenue in the quarter ending December 31, 2023 was $72.00K, a -31.43% decrease year-over-year.
Revenue (ttm)
$314.00K
Revenue Growth
-82.28%
P/S Ratio
3,130.15
Revenue / Employee
$3,340
Employees
94
Market Cap
982.87M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
Dec 31, 2016 | 3.48M | 939.00K | 37.00% |
Dec 31, 2015 | 2.54M | -1.78M | -41.25% |
Dec 31, 2014 | 4.32M | 4.00K | 0.09% |
Dec 31, 2013 | 4.32M | -90.04K | -2.04% |
Dec 31, 2012 | 4.41M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
OPKO Health | 863.50M |
Avanos Medical | 673.30M |
BioCryst Pharmaceuticals | 331.41M |
Simulations Plus | 64.67M |
EyePoint Pharmaceuticals | 46.02M |
Relay Therapeutics | 25.55M |
Mesoblast | 7.25M |
ARS Pharmaceuticals | 30.00K |
VRDN News
- 1 day ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 days ago - Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 - Business Wire
- 4 weeks ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm - PRNewsWire
- 2 months ago - Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference - Business Wire
- 2 months ago - Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 2 months ago - Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer - Business Wire
- 3 months ago - Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire